We have examined the distribution of HLA antigens in 70 multiple sclerosis (MS) patients divided in three groups defined according to clinical criteria: benign MS, severe MS, cerebellar MS. We have found a significant association between severe MS and HLA-DR2, and between benign MS of more than 15 years of evolution and HLA-DR3. We review previous work along the same line and conclude that the association of HLA antigens with "clinical subgroups of MS" could indicate a genetically based heterogeneity of the disease and offer help in establishing a prognosis. RESUME: Les sous-groupes cliniques de sclerose en plaques en relation avec I'HLA: alleles DR com me vraisemblables marqueurs de la progression de maladie Nous avons etudie la distribution des antigenes HLA chez 70 patients atteints de sclerose en plaques (SEP) regroupes, selon des criteres devolution clinique, en SEP benigne, SEP severe et SEP cerebelleuse. Nous avons retrouv6 une association significative entre la SEP severe et le HLA-DR2 d'une part, et entre la SEP benigne de plus de 15 ans devolution et le HLA-DR3 d'autre part. Nous resumons les publications anterieures du meme ordre et concluons que l'association entre des antigenes HLA et des sous-groupes cliniques de la SEP peuvent indiquer une heterogeneite de la maladie fondee genetiquement et contribuer a la formulation du pronostic evolutif.
Multiple sclerosis (MS) is known to be associated with certain HLA alleles in some populations, mostly of Caucasian extraction. The most constant association is with DR2 (Ebers, 1983) . The significance of this association is not clear and the study of MS multiplex families has further obscured the issue (Ebers and Paty, 1982 & 1983) .
It has now been shown that, for example, in diabetes, myasthenia gravis and systemic lupus erythematosus different clinical sub-groups of these diseases are associated with different HLA alleles (Cudworth, 1978; Engel, 1979; Bell and Rigby, 1984) .Having examined a large number of MS patients over the years, we have been impressed, despite the protean character of the disease, with the similarity of its course in some categories of patients. Clinical patterns of evolution would be reproduced from one patient to another. Patients with benign MS usually have an early onset, their bouts imply lesions of afferent structures, are short-lasted, and they recover totally, or almost so. Patients with severe MS tend to have critical lesions at onset, or a short time thereafter; impairment is diffuse. What we call cerebellar MS appeared to us as particularly characteristic, almost to the point of considering it as a distinct clinical entity: onset is usually in the early twenties, evolution is progressive, sex distribution is equal, cerebellar signs are diffuse and prominent. We do not know if this variability of expression of the disease is attributable to factors related to the disease agents, or to hostrelated factors, or to an interaction between the two. In order to study host-related factors, we have examined the HLA antigen distribution in what we consider to be well-characterized clinical sub-groups of MS: the benign form, the severe form and the cerebellar form. It is recognized that these sub-groups do not encompass the total range of clinical expression of MS. They were selected partially because of availability of patients and also because they allowed for strict criteria of definition.
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METHODS
Clinical definitions
The benign form of MS was defined as that allowing an evolution of 10 years or more from onset of symptoms, without ever reaching a level of 3 on the Kurtzke functional score. Because some patients have been known to change from a benign to a severe course between 10 and 15 years, and because this reversal is very rare after 15 years of evolution, this group was divided in 2 sub-groups, one of 10 to 14 years, the other of 15 years and more of evolution. The severe group included patients who reached a permanent score of 7.5 (or more) within 5 years of evolution. The cerebellar form of MS was defined as the development of severe and diffuse cerebellar impairment (including a posture or action tremor of the arms) combined with bilateral internuclear ophthalmoplegia, within 5 years of evolution.
Clinical material
This study was done retrospectively. Once clinical sub-groups were defined, charts were reviewed and suitable candidates were identified. Patients who were willing to collaborate were included in the study without further selection. The investigators who performed the HLA typings were unaware of the group to which the patient had been allocated, and the assignment of patients to clinical sub-groups was done before HLA results were available. Table 1 shows the clinical characteristics of the patients studied. A total of 70 patients were included. All were regularly attending the MS clinic, either at Notre-Dame Hospital (60 patients) or at the Montreal Neurological Institute (10 patients). All had definite MS according to Rose et al. criteria (Rose and Ellison, 1976) . Thirty-seven had had lumbar punctures, 23 of which showed oligoclonal bands and 26 elevated lgG levels. The duration of the illness averaged 13.1 years for the whole group. Age of onset ranged from 13 to 45 years, with an average of 24.5 years. All patients, as well as controls, were of Caucasian extraction; none were interrelated. The control population consisted of 125 unselected healthy subjects who had been typed for their HLA-A and B antigens in the course of a population genetics study. Sixty of them had been typed for HLA-DR antigens. This control population was typed in one laboratory (F.D.). HLA determination HLA typings were done in 2 laboratories. Forty-nine typings were done at the Blood Transfusion Service of the Canadian Red Cross in Montreal (F. Decary) and 21 at the Institut ArmandFrappier (G. Lamoureux). All of the control subjects were typed in the Red Cross laboratory. The standard NIH technique (Terasaki and McClelland, 1964) was used in both laboratories, for A and B series. Ten alleles could be determined for the HLA-A locus, while 15 alleles were determined for the HLA-B locus. For HLA-DR typing, B-cell enrichment was performed after sheep red blood cell rosetting. The sheep red blood cells had been previously treated either with neuraminidase or with aminoethylisothiouronium bromide. DR typing was done using the standardized microlymphocytotoxicity assay (Terasaki and Bernoro, 1978) . HLA-DR1 through DR-9 were determined. Commercially available (UCLA typing trays) and National Reference Laboratory plates (NRLT and NRLB) were used for HLA-A, B and DR typing.
Statistical analysis
The HLA-A, B and DR antigen frequencies were compared to that of the control population. For the whole group of patients, statistical significance was evaluated by the chi-square test with Yates correction with one degree of freedom. For the analysis of the sub-groups, Fisher's exact probability test was applied (Swinscow, 1978) . Table 2 shows the HLA alleles distribution in the patient population studied, as well as in the controls. The only significant deviations observed were for HLA -B40 (p < 0,05), and DR2 (p < 0.05). The frequencies of HLA-A3 and HLA-B7 are within the normal range.
RESULTS
The distribution of selected HLA-A, B and DR alleles in clinical sub-groups of MS is indicated in Table 3 . HLA-A and B antigens not shown were not significantly different from the controls. In the benign form HLA-DR2 was significantly increased only in the sub-group of 10 to 14 years of duration, whereas HLA-DR3 was significantly increased in the sub-group of 15 years or more of duration. In the severe form, both HLA-B7 and HLA-DR2 were increased to a significant level, while HLA-DR3 was normal and HLA-DR4 was decreased. In the cerebellar form, the antigen distribution was not different from the controls. DR2 is significantly increased in the severe form when compared with the benign form of more than 15 years of duration. The difference in DR3 frequency between the latter and the former group is not significant. Table 4 examines the distribution of HLA-DR2 and DR3 in relation to each other in the different groups. The occurrence of DR2 and DR3 together was not different than that seen in the normal control population. HLA-DR2 without DR3 was significantly increased in the severe form and in the benign group of 10tol4 years of duration. HLA-DR3 without DR2 was associated only with the benign group of 15 years or more of duration. Table 5 indicates the relative risk (R.R.) associated with the HLA-DR2 allele in the total population as well as in the clinical groups. The presence of DR2 confers a R.R. of 2.5 to all patients positive for that allele. Both the severe group and the benign sub-group of 10 to 14 years of duration carried a higher R.R., while a R.R. of less than 1 was associated with the benign sub-group of 15 years or more of evolution.
DISCUSSION
MS is usually considered as a single disease entity. Indeed, the histopathologic pattern of individual plaques and the immunoglobulin modifications are invariable from one patient to another. On the other hand, numerous factors seem to indicate that MS is a-syndrome grouping several more or less closely related diseases. These factors are: age of onset (early vs. late onset), type of involvement (isolated optic neuritis, Devic's syndrome, Schilder's disease, etc.),type of evolution (remitting, progressive), rate of progress (benign, severe). There are no obvious differences in MS in females as opposed to males, nor between sporadic and familial MS.
So far, few biological factors have supported the apparent clinical heterogeneity of MS. In a Danish study, Jersild et al. (1973) found an association between DR2 and a poor prognosis. This was confirmed by Raun et al. (1980) in a Danish population. Stendhal-Brodin et al. (1979) found in a Swedish population an association between DR2, high IgG values and a malignant course; the difference in DR2 frequency did not, however, reach statistical significance. Poser et al. (1981) found no difference in HLA distribution between benign and malignant MS in a German population. Engell et al. (1982) in a Danish population found that DR2 positive patients did experience a more rapid progression than DR2 negative patients. DR3 seemed to protect from this rapid progression of MS in DR2 positive patients. No association was found with other clinical parameters (severity of symptoms at onset, age of onset, remitting or progressive evolution). In contrast to these results, Delasnerie-Laupetre et al. (1982) state that in a group of 169 French patients, DR3 is an indicator of severity. Madigand et al. (1982) in a study of 261 patients from Rennes, France, have found an increase of DR2 in benign MS and an increase of DR3 in severe MS. DR2 positive patients responded to azathioprine treatment, while DR3 positive patients deteriorated under the same treatment.
In our population of MS patients HLA-DR2 is associated with the severe form of MS and HLA-DR3 is associated with the benign group of more than 14 years of duration. DR2 could be called an augmentor gene and DR3 a protector gene.
It is not surprising to find DR2 as a protector gene in some populations and as an augmentor gene in others (the same is true for DR3). Since no consistent markers have been found for the disease as a whole, the gene (or genes) influencing the prognosis of MS could be in linkage disequilibrium with different HLA-DR alleles in different populations.
The association of DR2 with both the severe form and the benign sub-group of 10 to 14 years of duration is intriguing. It could mean that DR2 positivity does not discriminate between a benign or a severe form of the disease. It could also indicate that 10 years duration is insufficient to consider a patient as having a benign form of MS. Fifteen years would be a more realistic time and DR3 is a reliable marker for such patients.
On clinical grounds, we had considered what we have called cerebellar MS as the most characteristic sub-group, because of the homogeneity of the clinical picture among the patients in this group. We considered them separately from the severe form because of the prominence of the cerebellar signs. However, no association was found for any allele in this group. This could be attributed to the small size of the group (13 patients). On the other hand, non-genetic factors could be responsible for the variety in the pattern of distribution of MS plaques.
The hypothesis underlying our work is that genetic factors are responsible for the variability in the clinical expression of MS, in the distribution of plaques, or in the rate of progression of the disease. Our results suggest that this might be the case, but the associations reported to date are neither strong nor constant. The significance of the association of MS with HLA alleles is still not known, and family studies have not brought conclusive answers (Ebers, 1982) .
We believe that further studies should be pursued, using larger patient populations and possibly other criteria for selecting groups. H LA typing may yield prognostic clues and help predict therapeutic responses in future clinical trials.
